Cipro Florinated (Like BAYCOL)

Cipro Facts -

Fluoride & Toxic Reactions

PFPC Health Alert - CIPRO

By Andreas Schuld, Wendy Small, Trent Harris

Parents of Fluoride Poisoned Children (PFPC)

Vancouver, BC, Canada

[email protected]

10-25-1

Dear All,

Two months ago we reported on the withdrawal of Bayer's

BAYCOL (Cerivastatin), a fluorinated drug (statin class) which

had caused deaths and serious adverse health effects worldwide (1,2,3).

BAYCOL had been found to cause muscle destruction/wasting -

a condition known as rhabdomyolysis - and displayed

compounded toxicity when used with other drugs. It had been

linked to at least 31 deaths.

We also showed how the adverse reactions documented with

BAYCOL were largely identical to those of numerous other

fluorinated drugs - all of which had been withdrawn from the

market in recent years (3).

ANTHRAX AND CIPRO

As a result of the current Anthrax scare another fluorinated

drug called CIPRO has received extensive media coverage

and the name has become familiar to millions almost overnight.

As soon as the first cases of anthrax resulting from suspicious

mail became known, there were wide reports of a hectic run on

this drug.

Mass hysteria seems present as governments, pharmacies and

individuals everywhere are stockpiling this drug. Pharmacies

are reporting record sales, and on-line prescription services

and Internet sites are found selling the drug at more than $7.00

per pill.

People everywhere, hyped into believing their flu-like

symptoms are caused by anthrax exposure and mis-informed

by rresponsible media reports, are taking CIPRO, and worse

yet - are giving it to their children.

WHAT IS CIPRO?

CIPRO is ciprofloxacin, a fluorinated quinolone, belonging to a class of

fluorinated antibiotics which also include enoxacin, fleroxacin,

temafloxacin, grepafloxacin, norfloxacin, sparfloxacin, tosufloxacin,

lomefloxacin, ofloxacin, etc..

Ciprofloxacin has been in use since 1987 for a variety of other indications

and is the most-widely used fluoroquinolone in humans and animals worldwide

(4).

In 2000 the FDA approved its use in treatment for inhalational anthrax under

its "accelerated approval" regulations (5). It had actually taken the

unusual step of urging Bayer - the sole manufacturer for all countries

except India - to file for such approval, supposedly in order to protect the

public from future terrorist attacks. The US Department of Defense had

already ordered reserves of CIPRO during the 1991 Gulf War (6).

ADVERSE EFFECTS:

As mentioned in the info on BAYCOL, temafloxacin and grepafloxacin are two

other fluoroquinolones now withdrawn from the market because they had caused

severe liver and renal damage - and deaths, just like fluorinated drugs from

other, different classifications (3).

The same information also exists for CIPRO.

Fatal liver failure associated with ciprofloxacin was reported in the Lancet

in 1994 (7, 8 - 150 more related refs).

Ciprofloxacin has been implicated in several cases of acute renal failure

and is the most established fluoroquinolone to cause such renal dysfunction

(4, 9, 10, 11 - 96 related refs).

FLUORIDE

The most common side-effects reported due to CIPRO (2-16%) are

gastrointestinal in nature and equal those reported when children

accidentally ingest "too much" fluoride from their toothpaste - such as

nausea, diarrhea, vomiting, and abdominal pain. Why?

Ciprofloxacin administration results in elevated serum fluoride levels (12).

In a series of tests evaluating the safety of ciprofloxacin in children,

serum fluoride levels increased after 12 hours in 79% of the children; on

day 7 the 24-hour urinary fluoride excretion was higher in 88.9% of children

observed (12).

Just as in the case of Baycol and other fluorinated drugs, CIPRO can cause

musculo-skeletal disorders such as rhabdomyolysis.

RHABDOMYOLYSIS

Since the introduction of fluoroquinolones on the market in 1987 more than

200 cases of rhabdomyolysis, tendinitis, tendon rupture etc. have been

reported in the literature (4,13,14,15).

In October 1994 the Japan Pharmaceutical Affairs Bureau was first to amend

the product information for fluoroquinolones to state that rhabdomyolysis

may occur (16).

In 1996 the FDA also issued directives to manufacturers to include warning

statements on all fluoroquinoline product inserts to alert patients and

caregivers to the potential for tendinitis and tendon rupture (17). Also in

1996 the Sri Lanka Drug Evaluation Sub-Committee decided that the product

information of fluoroquinolone antibiotics should include a warning stating:

"The onset of tendon pain calls for immediate withdrawal of fluoroquinolone

antibiotics." (18)

Achilles tendon rupture was shown to occur even after withdrawal of the

drug. Pathologically there was ultrastructure alteration in tendinocytes.

Just as in other cases of fluoride poisoning, studies in animals show that

magnesium deficiency aggravate the induced tendinopathy (14,19).

DRUG INTERACTIONS/DEATH:

Just as with BAYCOL, drug interactions with ciprofloxacin have resulted in

fatal outcomes due to potentiation of another drug's effects such

theophylline (4,20), methadone (21), or warfarin (22).

Just like BAYCOL and other fluorinated drugs, ciprofloxacin is a potent

inhibitor of the thyroid hormone-regulated P 450 enzyme system in the liver.

Of all fluoroquinolones, ciprofloxacin and enoxacin have shown the greatest

inhibitory capacity (4).

P450 IA2 prevents the metabolism/inactivation of methylxanthines, thereby

causing increased serum concentrations of drugs like theophylline and

caffeine, which in turn causes excess CNS and cardiac stimulation. As

mentioned above, CIPRO also elevates serum fluoride levels.

The liver has been identified as a target organ of fluoroquinolone toxicity

in animal studies (23). Already in the 1930s the same was shown by Bayer's

scientists such as Litzka or Knoll's Kraft who found that ALL organic

fluoride compounds tested (including those used for fluoroquinolone

production) interfered with thyroid hormone activity in liver and muscle

tissue. Meanwhile, they also showed "anti-bacterial" activity. This led to

the development of many fluorinated medications, including the numerous

compounds then used very successfully in the treatment of hyperthyroidism

(24,25). Kraft invented many fluorinated "medications". When it was

discovered that some of these organic compounds had the same detrimental

effects on teeth and bone as inorganic fluoride - although much less actual

F- was involved - he even filed patents on behalf of Knoll's using these

compounds in dental preparations (26,27).

Pregnant women should never take ciprofloxacin. CIPRO transfers through the

placenta. It inhibits P450 1A2 which has been shown to be critical for

neonatal survival by influencing the physiology of respiration in neonates.

Mice lacking this cytochrome died shortly after birth and showed symptoms of

severe respiratory distress (28). Respiratory distress is a side-effect of

ciprofloxacin also in adults (9). CIPRO also transfers through breastmilk.

RESISTANCE TO BACTERIA

Taking Ciprofloxacin can spur germs to mutate so that future bacterial

infections become untreatable. During the last decades a dramatic increase

in bacterial strains multiresistant to antibiotics, particlularly CIPRO -

has been reported (30, 31, 32). This increase has led to the occurrence of

incurable bacterial infections with a fatal outcome, and a particularly

serious problem in connection with hospital-acquired infections.

For example, Clostridium difficile has become one of the most common

acquired organisms in hospitals and long term care institutions. The

organism typically infects patients whose normal intestinal flora has been

disturbed by the administration of a broad-spectrum antibiotic such as

CIPRO. The diarrhea and inflammatory colitis associated with infection

represent a serious medical and surgical complication leading to increased

morbidity and mortality, and prolonging hospital stays by an average of

nearly three weeks. This is especially true for the elderly and for patients

with serious underlying diseases who are the most likely to develop the

infection. C. difficile associated diarrhea represents a major economic

burden to the healthcare system, conservatively estimated at $3-6 billion

per year in excess hospital costs in the U.S. alone (33).

The emergence of this "antibiotic resistance" is a result of the

overwhelming use of antibiotics in human and veterinary medicine. High rates

of fluoroquinolone resistance have been reported in many countries (30). For

example, in Asia CIPRO no longer can be used to treat gonorrhea, because the

disease has become resistant to the drug (34).

While the FDA in August 2000 approved CIPRO as the first-line treatment

against anthrax, a few months later (October 2000) it asked Bayer to remove

BAYTRIL - its equivalent for animals.

The FDA proposed banning the fluoroquinolones, which chicken and turkey

farmers have given to birds in their water since 1995 to help shield the

animals from infection. The agency acted after linking the drugs to a jump

in Campylobacter bacteria immune to the medications. Nearly 18 percent of

one common strain that infects humans are now immune to the very same drugs

which were considered the last line of defense against the infection.

Campylobacter is the leading bacterial cause of food poisoning in the United

States. Typically contracted through raw or undercooked meat, the germs

afflict more than 2 million people and kill some 500 each year in the US,

according to the CDC.

While Abbot voluntarily withdrew its version of the antibiotic (SaraFlox),

Bayer decided to challenge the FDA. The company had the option to comply

with the proposed ban or seek a hearing to determine whether such a move was

justified. Bayer refused to comply with the ban, a move that kicked off a

lengthy process that could take years (35). Meanwhile Bayer gets to poison

the world, AND make huge profits from it...

The AMA has advised its members to prescribe CIPRO very cautiously, saying

the worldwide problem of antibiotic resistance poses future dangers worse

than the anthrax attacks of today (Orlando Sentinel, October 20, 2001).

PHOTOSENSITIVITY

Photosensitization can result when light interacts with chemical agents in

the skin and eyes. This process can produce undesirable clinical

consequences, such as phototoxicity (i.e. exaggerated sunburn),

photoallergy, or photocarcinogenicity. People receiving CIPRO or any other

fluoroquinolone are warned on the product inserts not to expose themselves

to direct sunlight. Rashs develop on the areas exposed.

Upon UVA-irradiation the "fluorine" of numerous fluoroquinolones such as

lomefloxacin and fleroxacin, are "lost" as fluoride (36).

"We have discovered that anions can activate visual photoreceptors in the

dark. One anionic activator is the commonly used dental agent fluoride. The

data on in vitro preparations indicate that these anions modulate

photoreceptor biochemistry and may effect photoreceptors sensitivity..."

[Lewis A - "Fundamental studies in the molecular basis of laser induced

retinal damage" Annual report (Final) March 1 1979 - March 15, 1985 US DTIC

records (unclassified) AD#177817 (1985)]

MEDLINE has many articles on fluoride and photoreceptor activation (G

protein-coupled) (35).

OTHER CIPRO SIDE EFFECTS (29):

Abnormal dread or fear, achiness, bleeding in the stomach and/or intestines,

blood clots in the lungs, blurred vision, change in color perception,

chills, confusion, constipation, convulsions, coughing up blood, decreased

vision, depression, difficulty in swallowing, dizziness, double vision,

drowsiness, eye pain, fainting, fever, flushing, gas, gout flare up,

hallucinations, hearing loss, heart attack, hiccups, high blood pressure,

hives, inability to fall or stay asleep, inability to urinate, indigestion,

intestinal inflammation, involuntary eye movement, irregular heartbeat,

irritability, itching, joint or back pain, joint stiffness, kidney failure,

labored breathing, lack of muscle coordination, lack or loss of appetite,

large volumes of urine, light-headedness, loss of sense of identity, loss of

sense of smell, mouth sores, neck pain, nightmares, nosebleed, pounding

heartbeat, ringing in the ears, seizures, sensitivity to light, severe

allergic reaction, skin peeling, redness, sluggishness, speech difficulties,

swelling of the face, neck, lips, eyes, or hands, swelling of the throat,

tender, red bumps on skin, tingling sensation, tremors, unpleasant taste,

unusual darkening of the skin, vaginal inflammation, vague feeling of

illness, weakness, yellowed eyes and skin.

CIPRO causes fluoride poisoning. Will any practioner know how to deal with

this, considering that the ADA has shielded all from proper knowledge of

fluoride toxicity?

Andreas Schuld, Wendy Small, Trent Harris Parents of Fluoride Poisoned

Children (PFPC) Vancouver, BC, Canada [email protected]

1) "Poison Control: Fluorides, the deadly toxin within"

<http://www.prn.usm.my/bulletin/nst/2001/nst34.htmlhttp://www.prn.usm.my/bul
letin/nst/2001/nst34.html

2) 7AM - News: "Cures That Kill?"

<http://www.7amnews.com/2001/features/081801.shtmlhttp://www.7amnews.com/200
1/features/081801.shtml

3) Dr. Mercola - "Baycol - Another Fluoride Drug Bites the Dust" (PFPC News,

August 18, 2001)

<http://www.mercola.com/2001/aug/18/fluoride_drugs.htmhttp://www.mercola.com
/2001/aug/18/fluoride_drugs.htm

4) Clinical Toxicology Review - "What Are Fluoroquinolones?" CTR,

Massachusetts Poison Control System, Vol. 20, No. 3 (1997)

5) FDA TALK PAPER " APPROVAL OF CIPRO® FOR USE AFTER EXPOSURE TO

INHALATIONAL ANTHRAX" Food and Drug Administration, U.S. Department of

Health and Human Services Public Health Service 5600 Fishers Lane Rockville,

MD 20857 (2000)

6) CNN - Reuter's, July 27, 2000

7) Fuchs S, Simon Z, Brezis M - "Fatal hepatic failure associated with

ciprofloxacin" Lancet 242:738-739 (1994)

8) 150+ Related References : CIPRO - Liver

<http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?form=4&db=m&term=cipro&;
lhttp://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?form=4&db=m&term=cipro&;
l

ive r

9) Hootkins R, Fenves AZ, Stephens MK - "Acute renal failure secondary to

oral ciprofloxacin therapy: a presentation of three cases and a review of

the literature" Clin Nephrol 32(2):75-8 (1989)

10) Reece RJ, Nicholls AJ - "Ciprofloxacin-induced acute interstitial

nephritis" Nephrol Dial Transplant 11(2):393 (1996)

11) 90+ Related References : CIPRO - Renal failure

<http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?form=4&db=m&term=cipro&;
rhttp://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?form=4&db=m&term=cipro&;
r

ena l&failure

12) Pradhan KM, Arora NK, Jena A, Susheela AK, Bhan MK - "Safety of

ciprofloxacin therapy in children: magnetic resonance images, body fluid

levels of fluoride and linear growth" Acta Paediatr 84(5):555-60 (1995)

13) Australian Adverse Drug Reactions Bulletin - Vol. 16, No. 2 (May 1997)

14) Ramanujam TR - "Fluoroquinolones - A Review" (2001)

<http://www.mcsindia.org/doctors/Epharma/january.asphttp://www.mcsindia.org/
doctors/Epharma/january.asp

15) Petition to Require a Warning on All Fluoroquinolone Antibiotics (HRG

Publication #1399)

<http://www.citizen.org/publications/release.cfm?ID=6595http://www.citizen.o
rg/publications/release.cfm?ID=6595

16) Information on Adverse Reactions to Drugs No.128, October 1994

17) FDA Medical Bulletin - Vol. 26, No.3 (October 1996)

18) 27th Meeting of the Drug Evaluation Sub-Committee, Ministry of Health,

Colombo (November 1996)

19) Shakibaei M, de Souza P, van Sickle D, Stahlmann R - "Biochemical

changes in Achilles tendon from juvenile dogs after treatment with

ciprofloxacin or feeding a magnesium-deficient diet" Arch Toxicol

75(6):369-74 (2001)

20) Clinical Toxicology Review, Vol. 20, No. 3 (1997)

21) Herrlin K, Segerdahl M, Gustafsson LL, Kalso E - "Methadone,

ciprofloxacin, and adverse drug reactions" Lancet 356(9247):2069-70 (2000)

22) Ellis RJ, Mayo MS, Bodensteiner DM - "Ciprofloxacin-warfarin

coagulopathy: a case series" Am J Hematol 63(1):28-31 (2000)

23) Guzman A, Garcia C, Demestre I - "Subchronic toxicity of the new

quinolone antibacterial agent irloxacin in beagle dogs"

Arzneimittelforschung 50(5):485-94 (2000)

24) Kraft K - "Über die Synthese einiger aromatischer Fluorverbindungen"

Knoll Research, Chem Ber. 84(2):150-156 (1951) (describes manufacturing

processes of numerous organic fluorides, after it was shown that all organic

fluoride compounds displayed stronger anti-thyroid activity than the mere

"fluoride ion")

25) Kraft K, Dengel F - "Über die Synthese einiger aromatischer

Fluorverbindungen, II. Mitteilung" Chem Ber 85(6):577-582 (1952) (more

reports on organic fluoride investigations..."in regards to their

characteristics in lowering BMR as well as anti-bacterial activity")

26) Zutavern EP, Kraft K - "Verfahren zur Herstellung von organischen Salzen

der Fluorwasserstoffsäure" German Patent No. 855118, granted Dec. 5, 1950

(Knoll AG) (Kraft patent on the same organic fluoride compounds used

previously in the treatment of hyperthyroidism, now patented as anti-caries

agents!)

27) Eichler O, Kraft K - "Verfahren zur Herstellung einer alkalischen,

seifenfreien, reagibles Fluor neben Calciumcarbonat enthaltenden Zahnpasta"

German Patent No. 971375, granted Aug. 28, 1951 (Knoll AG) (patent

describing the use of ethanol-amino-hydrofluorides in toothpaste...)

28) Pineau T, Fernandez-Salguero P, Lee SS, McPhail T, Ward JM, Gonzalez

FJ - "Neonatal lethality associated with respiratory distress in mice

lacking cytochrome P450 1A2" Proc Natl Acad Sci U S A 92(11):5134-8 (1995)

29) Cipro Monograph

<http://www.healthsquare.com/pdrfg/pd/monos/cipro.htmhttp://www.healthsquare
.com/pdrfg/pd/monos/cipro.htm

30) Coronado VG, Edwards JR, Culver DH, Gaynes RP - "Ciprofloxacin

resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus

in the United States. National Nosocomial Infections Surveillance (NNIS)

System" Infect Control Hosp Epidemiol 16(2):71-5 (1995)

31) Smith KE, Besser JM, Hedberg CW, Leano FT, Bender JB, Wicklund JH,

Johnson BP, Moore KA, Osterholm MT - "Quinolone-resistant Campylobacter

jejuni infections in Minnesota, 1992-1998" N Engl J Med

340(20):1525-32(1999)

32) CDC Special Report : "Emerging Mechanisms of Fluoroquinolone Resistance"

David C. Hooper Massachusetts General Hospital, Harvard Medical School,

Boston, Massachusetts, USA

33) Kurtz CI, Fitzpatrick R - "Anionic polymers as toxin binders and

antibacterial agents" US Patent 6,290,946, GelTex Pharmaceuticals, Inc.

(2000)

34) Orlando Sentinel, October 20, 2001

35) Bayer Balks at Banning Poultry Antibiotic - FDA, citing resistance,

seeks removal" By Adam Marcus HealthScout Reporter, Dec. 1, 2000

36) Chignell CF - "Mechanisms of chemically induced photosensitivity" Crisp

Data Base National Institutes Of Health, CRISP/99/ES50046-20 (1998).

37) Photoreceptor/fluoride - 50+ References



--
The silver-list is a moderated forum for discussion of colloidal silver.

To join or quit silver-list or silver-digest send an e-mail message to: 
[email protected]  -or-  [email protected]
with the word subscribe or unsubscribe in the SUBJECT line.

To post, address your message to: [email protected]
Silver-list archive: http://escribe.com/health/thesilverlist/index.html
List maintainer: Mike Devour <[email protected]>